Vitreoretinal procedures should be treated as day cases

Article

Patients who are currently hospitalized overnight for vitreoretinal surgery could safely be treated as day cases, thus providing significant improvements in efficiency, according to a report published in the February issue of Eye.

Patients who are currently hospitalized overnight for vitreoretinal surgery could safely be treated as day cases, thus providing significant improvements in efficiency, according to a report published in the February issue of Eye.

Vaughn Tanner and colleagues from the Royal Berkshire and Battle NHS trust, Windsor, UK conducted a retrospective and prospective study to examine the feasibility and safety of routine day case vitreoretinal surgery.

A total of 100 patients (50 retrospective and 50 prospective) undergoing vitreoretinal surgery within the Royal Berkshire NHS trust were included. The retrospective arm of the study aimed to identify the frequency and type of acute ophthalmic or medical intervention during a postoperative overnight stay and the results were used to alter management in the prospective group. The prospective arm included both patients staying overnight and day cases. All patients in the prospective group had routine subtenon marcaine anaesthesia together with prophylactic preoperative intravenous acetazolamide. Patients deemed fit postoperatively, were offered overnight ward discharge with obligatory next day review.

In the retrospective group, 56% required oral non-steroidal analgesia on the day of surgery and one patient required narcotic analgesia. Twenty-two percent of patients required intraocular pressure (IOP) control on the day of surgery and one patient needed medical intervention in the form of urinary catheterization. A total of 19 patients required intervention on next-day review. In the prospective group, 86% preferred day case and were suitable, 6% were suitable but preferred overnight stay and 8% were deemed unfit for discharge. No patient discharged returned as a casualty overnight and only one patient required a topical beta-blocker for the control of IOP on next-day review.

It was the conclusion of the authors that most vitreoretinal procedures could be treated as day cases, which would be less stressful for patients and better for efficiency.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.